Spark Therapeutics Company Profile (NASDAQ:ONCE)

About Spark Therapeutics (NASDAQ:ONCE)

Spark Therapeutics logoSpark Therapeutics, Inc. is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial. Its product investigational candidate, voretigene neparvovec, is intended to treat a genetic blinding condition or inherited retinal disease (IRD). The programs targeting hematologic disorders include SPK-FIX, for which the lead product candidate, SPK-9001, is in a Phase I/II clinical trial for the treatment of hemophilia B, as well as SPK-FVIII for the treatment of hemophilia A. In its SPK-FVIII program for the treatment of hemophilia A, the Company has initiated a dose-escalating Phase I/II clinical trial for its lead product candidate, SPK-8011.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ONCE
  • CUSIP: N/A
  • Web:
  • Market Cap: $2.56 billion
  • Outstanding Shares: 31,250,000
Average Prices:
  • 50 Day Moving Avg: $85.32
  • 200 Day Moving Avg: $85.32
  • 52 Week Range: $35.07 - $91.75
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -16.51
  • P/E Growth: -0.59
Sales & Book Value:
  • Annual Revenue: $20.36 million
  • Price / Sales: 125.66
  • Book Value: $7.31 per share
  • Price / Book: 11.20
  • EBITDA: ($165,640,000.00)
  • Net Margins: -962.72%
  • Return on Equity: -59.74%
  • Return on Assets: -52.08%
  • Current Ratio: 6.09%
  • Quick Ratio: 6.09%
  • Average Volume: 499,563 shs.
  • Beta: 3.38
  • Short Ratio: 10.74

Frequently Asked Questions for Spark Therapeutics (NASDAQ:ONCE)

What is Spark Therapeutics' stock symbol?

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

How were Spark Therapeutics' earnings last quarter?

Spark Therapeutics, Inc. (NASDAQ:ONCE) issued its earnings results on Wednesday, August, 2nd. The company reported ($1.89) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($1.75) by $0.14. The business earned $1.48 million during the quarter, compared to the consensus estimate of $1.33 million. Spark Therapeutics had a negative return on equity of 59.74% and a negative net margin of 962.72%. The business's revenue was up 14.7% on a year-over-year basis. During the same period in the prior year, the business earned ($1.04) EPS. View Spark Therapeutics' Earnings History.

Where is Spark Therapeutics' stock going? Where will Spark Therapeutics' stock price be in 2017?

17 analysts have issued 12 month price targets for Spark Therapeutics' shares. Their predictions range from $28.00 to $111.00. On average, they expect Spark Therapeutics' share price to reach $91.63 in the next twelve months. View Analyst Ratings for Spark Therapeutics.

What are analysts saying about Spark Therapeutics stock?

Here are some recent quotes from research analysts about Spark Therapeutics stock:

  • 1. Chardan Capital analysts commented, "We also see it as a important positive on Spark corporate governance that, e.g. during the panel, Spark provided caution to the panel attendees when panelists seemed interested in the potential for Luxturna re-treatment to further improve vision by treating more of the retina. (Spark noted that the company had not yet generated such data and responsibly urged caution.) After the unanimous backing of the panel, Luxturna, which has a PDUFA date of 12 January 2018, could achieve a number of firsts if approved, i.e." (10/13/2017)
  • 2. Cowen and Company analysts commented, "The FDA’s briefing documents appear mostly benign with most discussion centered." (10/10/2017)
  • 3. According to Zacks Investment Research, "Spark Therapeutics, Inc. offers gene therapy. The Company's product candidate consist of SPK-RPE65, SPK-CHM, SPK-FIX which are in different clinical phases, for the treatment of additional blinding conditions, hematologic disorders and neurodegenerative diseases. Spark Therapeutics, Inc. is based in Philadelphia, Pennsylvania. " (8/5/2017)
  • 4. Cantor Fitzgerald analysts commented, "2017 – Year of First Gene Therapy Approval in U.S.? Management reiterated its confidence in filing its rolling BLA in early 2017, and highlighted that the company has completed the necessary manufacturing runs to support its submission. Outstanding items for the filing include finalization of stability testing and CMC module write-up. We believe the timing of the filing could lead to the first approved gene therapy in the U.S. this year and remind investors that the FDA previously amended its granted orphan designation for voretigene neparvovec to cover inherited retinal diseases caused by biallelic RPE65 mutations." (2/23/2017)
  • 5. Stifel Nicolaus analysts commented, "Management's 4Q16 earnings announcement/call contained minimally-incremental insight on many of the data catalysts still anticipated for 1H17. We believe management's commentary around the current state of pre-commercialization activities for voretigene neparvovec (VN) ' including directionally positive feedback on both the access and reimbursement fronts ' should ameliorate some of the near-term concerns of those investors anticipating pricing/reimbursement to potentially represent a source of headline risk. We believe anticipation around a number of key near-term data catalysts ' including early-FY17 SPK-7001 data in choroideremia, updated early-April SPK-9001 data in hemophilia B, and preliminary mid-FY17 SPK-8011 data ' should keep ONCE shares at the forefront of relevancy over the coming months. Estimates largely unchanged." (2/23/2017)

Are investors shorting Spark Therapeutics?

Spark Therapeutics saw a decrease in short interest in September. As of September 29th, there was short interest totalling 2,255,175 shares, a decrease of 48.1% from the September 15th total of 4,343,511 shares. Based on an average daily volume of 435,854 shares, the days-to-cover ratio is currently 5.2 days. Approximately 7.1% of the shares of the stock are short sold.

Who are some of Spark Therapeutics' key competitors?

Who are Spark Therapeutics' key executives?

Spark Therapeutics' management team includes the folowing people:

  • Steven M. Altschuler M.D., Independent Chairman of the Board
  • Katherine A. High M.D., President, Chief Scientific Officer, Director
  • Jeffrey D. Marrazzo, Chief Executive Officer, Co-Founder, Director
  • Stephen W. Webster, Chief Financial Officer
  • John P Furey, Chief Operating Officer
  • Federico Mingozzi Ph.D., Chief Scientific Officer
  • Joseph W. La Barge Esq., General Counsel
  • Daniel R. Faga, Chief Business Officer
  • Lars G. Ekman M.D., Ph.D., Independent Director
  • Anand Mehra M.D., Independent Director

When did Spark Therapeutics IPO?

(ONCE) raised $88 million in an IPO on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

How do I buy Spark Therapeutics stock?

Shares of Spark Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Spark Therapeutics' stock price today?

One share of Spark Therapeutics stock can currently be purchased for approximately $81.87.

MarketBeat Community Rating for Spark Therapeutics (NASDAQ ONCE)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  245 (Vote Outperform)
Underperform Votes:  210 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Spark Therapeutics and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Spark Therapeutics (NASDAQ:ONCE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 15 Buy Ratings
Consensus Rating:Buy (Score: 2.82)
Consensus Price Target: $91.63 (11.92% upside)
Consensus Price Target History for Spark Therapeutics (NASDAQ:ONCE)
Price Target History for Spark Therapeutics (NASDAQ:ONCE)
Analysts' Ratings History for Spark Therapeutics (NASDAQ:ONCE)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/16/2017SunTrust Banks, Inc.Set Price TargetBuy$101.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetOverweight$104.00 -> $107.00N/AView Rating Details
10/13/2017Cantor FitzgeraldLower Price TargetBuy$105.00 -> $94.00N/AView Rating Details
10/13/2017Stifel NicolausReiterated RatingBuy -> Buy$92.00 -> $101.00N/AView Rating Details
10/13/2017BMO Capital MarketsReiterated RatingOutperform$89.00 -> $101.00N/AView Rating Details
10/13/2017Chardan CapitalReiterated RatingBuy$100.00N/AView Rating Details
10/12/2017Raymond James Financial, Inc.Initiated CoverageOutperform -> Outperform$96.00N/AView Rating Details
10/10/2017Cowen and CompanyReiterated RatingBuy$95.00N/AView Rating Details
10/10/2017Jefferies Group LLCReiterated RatingBuy$95.00N/AView Rating Details
10/6/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy -> Buy$111.00N/AView Rating Details
9/14/2017Royal Bank Of CanadaInitiated CoverageOutperform -> Outperform$100.00MediumView Rating Details
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$83.00HighView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageOutperform$87.00MediumView Rating Details
6/28/2017William BlairInitiated CoverageOutperform -> OutperformHighView Rating Details
5/10/2017WedbushReiterated RatingUnderperform$28.00MediumView Rating Details
2/22/2017J P Morgan Chase & CoSet Price TargetBuy$82.00N/AView Rating Details
2/9/2017Leerink SwannInitiated CoverageOutperform -> Outperform$85.00N/AView Rating Details
12/24/2015WunderlichDowngradeBuy -> HoldN/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Spark Therapeutics (NASDAQ:ONCE)
Earnings by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Earnings History by Quarter for Spark Therapeutics (NASDAQ ONCE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/2/2017Q2 2017($1.75)($1.89)$1.33 million$1.48 millionViewListenView Earnings Details
5/9/2017Q1 2017($1.36)($1.70)$1.35 million$1.27 millionViewListenView Earnings Details
2/22/2017Q416($1.12)($1.21)$1.32 million$16.30 millionViewListenView Earnings Details
11/3/2016Q316($1.01)($1.07)$1.26 million$1.30 millionViewN/AView Earnings Details
8/10/2016Q216($0.97)($1.04)$1.17 million$1.29 millionViewListenView Earnings Details
5/4/2016Q116($0.84)($0.95)$1.48 million$1.29 millionViewListenView Earnings Details
3/9/2016Q415($0.73)($0.24)$1.30 million$17.20 millionViewListenView Earnings Details
11/4/2015Q315($0.48)($0.70)$4.43 million$1.30 millionViewListenView Earnings Details
8/5/2015Q215($0.13)($0.60)$4.50 million$1.29 millionViewListenView Earnings Details
5/6/2015Q115($0.61)($0.58)$1.20 million$1.30 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Spark Therapeutics (NASDAQ:ONCE)
2017 EPS Consensus Estimate: ($6.80)
2018 EPS Consensus Estimate: ($5.95)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.75)($1.32)($1.44)
Q2 20175($1.77)($1.71)($1.73)
Q3 20175($1.89)($1.64)($1.78)
Q4 20175($1.96)($1.64)($1.85)
Q1 20182($1.99)($1.67)($1.83)
Q2 20182($1.73)($1.43)($1.58)
Q3 20182($1.40)($1.09)($1.25)
Q4 20182($1.36)($1.22)($1.29)
(Data provided by Zacks Investment Research)


Dividend History for Spark Therapeutics (NASDAQ:ONCE)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Spark Therapeutics (NASDAQ:ONCE)
Insider Ownership Percentage: 7.30%
Institutional Ownership Percentage: 77.84%
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Institutional Ownership by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Insider Trades by Quarter for Spark Therapeutics (NASDAQ:ONCE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/26/2017Katherine A HighInsiderSell5,000$86.16$430,800.00View SEC Filing  
9/21/2017Hospital Of Philade Children'sDirectorSell1,000,000$84.63$84,630,000.00View SEC Filing  
9/19/2017Daniel FagaInsiderSell1,500$85.00$127,500.00View SEC Filing  
9/12/2017Daniel FagaInsiderSell6,000$82.50$495,000.00View SEC Filing  
9/7/2017Daniel FagaInsiderSell3,000$85.02$255,060.00View SEC Filing  
9/5/2017Barge Joseph LaInsiderSell5,500$81.00$445,500.00View SEC Filing  
8/29/2017Katherine A HighInsiderSell10,000$80.25$802,500.00View SEC Filing  
8/23/2017Jeffrey D MarrazzoCEOSell21,350$80.01$1,708,213.50View SEC Filing  
8/15/2017Stephen W WebsterCFOSell10,000$79.38$793,800.00View SEC Filing  
8/11/2017Jeffrey D MarrazzoCEOSell15,000$75.10$1,126,500.00View SEC Filing  
8/2/2017Jeffrey D MarrazzoCEOSell28,650$80.01$2,292,286.50View SEC Filing  
7/31/2017Stephen W WebsterCFOSell2,337$71.12$166,207.44View SEC Filing  
7/25/2017Katherine A HighInsiderSell10,000$72.53$725,300.00View SEC Filing  
7/24/2017Anand MehraDirectorSell211,858$70.15$14,861,838.70View SEC Filing  
7/24/2017Daniel FagaInsiderSell3,000$70.00$210,000.00View SEC Filing  
7/5/2017Jeffrey D MarrazzoCEOSell5,669$65.00$368,485.00View SEC Filing  
6/29/2017Daniel FagaInsiderSell4,500$62.71$282,195.00View SEC Filing  
6/27/2017Katherine A HighInsiderSell10,000$60.96$609,600.00View SEC Filing  
6/21/2017Anand MehraDirectorSell6,302$65.00$409,630.00View SEC Filing  
6/21/2017Jeffrey D MarrazzoCEOSell9,331$65.00$606,515.00View SEC Filing  
6/19/2017Katherine A HighInsiderSell10,000$60.00$600,000.00View SEC Filing  
6/19/2017Stephen W WebsterCFOSell7,663$60.00$459,780.00View SEC Filing  
6/7/2017Barge Joseph LaGeneral CounselSell5,000$55.00$275,000.00View SEC Filing  
4/25/2017Katherine A HighInsiderSell15,000$55.33$829,950.00View SEC Filing  
4/25/2017Stephen W WebsterCFOSell10,000$55.18$551,800.00View SEC Filing  
4/24/2017Katherine A HighInsiderSell2,060$55.01$113,320.60View SEC Filing  
4/24/2017Stephen W WebsterCFOSell1,898$55.00$104,390.00View SEC Filing  
4/3/2017Barge Joseph LaGeneral CounselSell5,000$52.73$263,650.00View SEC Filing  
3/1/2017Anand MehraDirectorSell84,654$65.02$5,504,203.08View SEC Filing  
3/1/2017Barge Joseph LaGeneral CounselSell5,000$64.41$322,050.00View SEC Filing  
2/28/2017Anand MehraDirectorSell25,274$65.02$1,643,315.48View SEC Filing  
2/27/2017Anand MehraDirectorSell41,910$65.02$2,724,988.20View SEC Filing  
2/16/2017Anand MehraDirectorSell35,347$65.03$2,298,615.41View SEC Filing  
2/7/2017Anand MehraDirectorSell25,334$65.06$1,648,230.04View SEC Filing  
12/16/2016Anand MehraDirectorSell349,656$53.46$18,692,609.76View SEC Filing  
12/15/2016Barge Joseph LaInsiderSell3,000$52.98$158,940.00View SEC Filing  
12/13/2016Anand MehraDirectorSell122,532$55.17$6,760,090.44View SEC Filing  
11/14/2016Katherine A HighInsiderSell10,000$60.30$603,000.00View SEC Filing  
10/17/2016Jeffrey D MarrazzoCEOSell5,000$54.66$273,300.00View SEC Filing  
10/3/2016Barge Joseph LaInsiderSell3,000$60.14$180,420.00View SEC Filing  
9/16/2016Jeffrey D MarrazzoCEOSell10,000$62.68$626,800.00View SEC Filing  
9/15/2016Katherine A HighInsiderSell10,000$60.37$603,700.00View SEC Filing  
8/16/2016Hospital Of Philade Children'sDirectorSell1,000,000$60.90$60,900,000.00View SEC Filing  
8/11/2016Anand MehraDirectorSell29,963$60.13$1,801,675.19View SEC Filing  
8/11/2016Jeffrey D MarrazzoCEOSell16,970$60.04$1,018,878.80View SEC Filing  
8/10/2016Katherine A HighInsiderSell1,890$60.00$113,400.00View SEC Filing  
8/8/2016Anand MehraDirectorSell100$60.47$6,047.00View SEC Filing  
8/8/2016Jeffrey D MarrazzoCEOSell900$60.24$54,216.00View SEC Filing  
8/8/2016Katherine A HighInsiderSell500$60.24$30,120.00View SEC Filing  
8/4/2016Anand MehraDirectorSell5,064$60.00$303,840.00View SEC Filing  
8/3/2016Jeffrey D MarrazzoCEOSell16,530$60.02$992,130.60View SEC Filing  
8/3/2016Katherine A HighInsiderSell17,610$60.02$1,056,952.20View SEC Filing  
8/1/2016Anand MehraDirectorSell22,665$60.03$1,360,579.95View SEC Filing  
8/1/2016Jeffrey D MarrazzoCEOSell12,348$60.03$741,250.44View SEC Filing  
8/1/2016Katherine A HighInsiderSell13,983$60.02$839,259.66View SEC Filing  
7/18/2016Jeffrey D MarrazzoCEOSell5,000$52.53$262,650.00View SEC Filing  
7/15/2016Coelho Rogerio VivaldiInsiderSell7,000$53.03$371,210.00View SEC Filing  
7/5/2016Barge Joseph LaInsiderSell3,000$52.24$156,720.00View SEC Filing  
6/20/2016Hospital Of Philade Children'sMajor ShareholderSell1,000,000$42.30$42,300,000.00View SEC Filing  
6/15/2016Jeffrey D MarrazzoCEOSell5,000$46.49$232,450.00View SEC Filing  
5/31/2016Anand MehraDirectorSell500$60.00$30,000.00View SEC Filing  
5/23/2016Katherine A HighInsiderSell10,000$54.42$544,200.00View SEC Filing  
5/20/2016Barge Joseph LaInsiderSell10,000$47.65$476,500.00View SEC Filing  
5/20/2016Stephen W WebsterCFOSell20,000$50.39$1,007,800.00View SEC Filing  
5/19/2016Jeffrey D MarrazzoCEOSell25,000$46.01$1,150,250.00View SEC Filing  
4/21/2016Coelho Rogerio VivaldiInsiderSell7,000$40.02$280,140.00View SEC Filing  
12/28/2015Hospital Of Philade Children'sMajor ShareholderSell131,505$44.18$5,809,890.90View SEC Filing  
12/21/2015Hospital Of Philade Children'sMajor ShareholderSell1,000,000$44.18$44,180,000.00View SEC Filing  
12/1/2015Katherine A HighInsiderSell10,000$55.31$553,100.00View SEC Filing  
11/27/2015Anand MehraDirectorSell22,961$60.01$1,377,889.61View SEC Filing  
11/16/2015Katherine A HighInsiderSell10,000$53.77$537,700.00View SEC Filing  
11/12/2015Anand MehraDirectorSell130,605$60.11$7,850,666.55View SEC Filing  
10/14/2015Katherine A. HighinsiderSell30,000$49.34$1,480,200.00View SEC Filing  
10/13/2015Katherine A. HighinsiderSell10,000$48.00$480,000.00View SEC Filing  
10/12/2015Jeffrey D. MarrazzoCEOSell75,000$48.35$3,626,250.00View SEC Filing  
10/9/2015Jeffrey D. MarrazzoCEOSell75,000$47.82$3,586,500.00View SEC Filing  
10/8/2015Anand MehraDirectorSell529,544$45.46$24,073,070.24View SEC Filing  
10/7/2015Coelho Rogerio VivaldiinsiderSell41,000$48.85$2,002,850.00View SEC Filing  
10/7/2015Stephen W. WebsterCFOSell20,000$48.86$977,200.00View SEC Filing  
10/7/2015Steven AltschulerDirectorBuy5,000$49.11$245,550.00View SEC Filing  
2/4/2015Anand MehraDirectorBuy225,000$23.00$5,175,000.00View SEC Filing  
2/4/2015Hospital Of Philade Children'sMajor ShareholderBuy100,000$23.00$2,300,000.00View SEC Filing  
2/4/2015Stephen W WebsterCFOBuy2,500$23.00$57,500.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Spark Therapeutics (NASDAQ:ONCE)
Latest Headlines for Spark Therapeutics (NASDAQ:ONCE)
Loading headlines, please wait.



Spark Therapeutics (ONCE) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.